Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
19 Mars 2024 - 1:00PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study of optical genome mapping (OGM) in
hereditary breast and ovarian cancer (HBOC) syndrome showing that
when tumors exhibited higher overall numbers of structural
variations (SVs) they tended to have more mutated genes and altered
signaling pathways, which may correlate with poor prognosis, tumor
progression and chemotherapy resistance. Researchers also found
that OGM was able to detect chromothripsis events and novel gene
fusions in cancer tissues with high accuracy, including novel gene
fusions that were not detected by other methods.
HBOC syndrome is estimated to cause 5-10% of all breast cancers
and is commonly characterized by harmful germline mutations in
the BRCA1 or BRCA2 genes. Due to limitations
inherent in common methods of genome analysis,
researchers have limited knowledge regarding the potential
impact of structural abnormalities and SV heterogeneity in
HBOC-related cancers. The study authors selected OGM for this
analysis due to its ability to detect multiple classes of SVs with
genome-wide coverage, high resolution and accuracy.
Study authors categorized the HBOC-related breast cancer samples
into two groups, SVhigh and SVlow, based on the number of SVs
detected by OGM, high or low Ki-67 expression, and the number of
mutated genes and altered signaling pathways. The authors noted
that SVhigh samples were associated with higher Ki-67
expression and higher homologous recombination deficiency (HRD)
scores, indicating that genetic alterations may have potential
predictive and therapeutic significance. The SVhigh samples
also showed higher numbers of chromothripsis events and novel gene
fusions than the SVlow samples. Eight novel gene fusions were
identified by OGM, including three that had not previously been
detected by other methods of analysis. These gene fusions may be
involved in drug resistance and tumor development.
“We are pleased to see the publication of this study, which
highlights OGM as a promising tool for detecting
novel variants in HBOC-related breast cancer that have
oncogenic potential. We believe the comprehensive assessment of the
role SVs play in breast cancers with abnormal DNA repair functions
might expand our current understanding of disease progression and
precision medicine in breast cancer," commented Erik Holmlin,
PhD, president and chief executive officer of Bionano.
The paper is available
at: https://www.imrpress.com/journal/FBL/29/1/10.31083/j.fbl2901002/htm
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “may,” “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the ability and utility of OGM to detect SVs in samples suspected
of HBOC syndrome; and the ability and utility of OGM to detect
chromothripsis events and novel gene fusions in cancer tissues with
high accuracy, including novel gene fusions that were not detected
by other methods. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and potential future
bank failures, supply chain disruptions, global pandemics,
inflation and the ongoing conflicts between Ukraine and Russia and
Israel and Hamas, on our business and the global economy; general
market conditions; the failure of OGM to detect SVs in samples
suspected of HBOC syndrome; the failure of OGM to detect
chromothripsis events and novel gene fusions in cancer tissues with
high accuracy, including novel gene fusions that were not detected
by other methods; study results that differ or contradict the
results reported in the study referenced in this press release;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
changes in our strategic and commercial plans; our need and ability
to obtain sufficient financing to fund our strategic plans and
commercialization efforts, our ability to effectively manage our
uses of cash, and our ability to continue as a “going concern”; the
ability of medical and research institutions to obtain funding to
support adoption or continued use of our technologies; and the
risks and uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2023 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024